NCT04696393View on ClinicalTrials.gov

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 6, 2021

Primary Completion Date

March 19, 2021

Study Completion Date

March 19, 2021

Conditions
Healthy Volunteers
Interventions
DRUG

Mitapivat tablet

Oral tablets

Trial Locations (1)

78744

PPD Development, LP, Austin

Sponsors
All Listed Sponsors
lead

Agios Pharmaceuticals, Inc.

INDUSTRY

NCT04696393 - A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants | Biotech Hunter | Biotech Hunter